Cart
sales@molnova.com
4-Chlorothieno[3,2-d]pyrimidine
CAS No. 16269-66-2
4-Chlorothieno[3,2-d]pyrimidine( —— )
Catalog No. M36467 CAS No. 16269-66-2
4-Chlorothieno[3,2-d]pyrimidine is a useful organic compound for research related to life sciences. The catalog number is T7256 and the CAS number is 16269-66-2.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 33 | In Stock |
|
| 25MG | 52 | In Stock |
|
| 50MG | 75 | In Stock |
|
| 100MG | 106 | In Stock |
|
| 500MG | 266 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name4-Chlorothieno[3,2-d]pyrimidine
-
NoteResearch use only, not for human use.
-
Brief Description4-Chlorothieno[3,2-d]pyrimidine is a useful organic compound for research related to life sciences. The catalog number is T7256 and the CAS number is 16269-66-2.
-
Description4-Chlorothieno[3,2-d]pyrimidine is a useful organic compound for research related to life sciences. The catalog number is T7256 and the CAS number is 16269-66-2.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number16269-66-2
-
Formula Weight170.61
-
Molecular FormulaC6H3ClN2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESClC1=C2SC=CC2=NC=N1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Xenopsin
Xenopsin, a neurotensin-like octapeptide, Xenopsin is an inhibitor of Tetragastrin stimulated gastric acid secretion.
-
Apraglutide TFA (129...
Apraglutide TFA (FE 203799 TFA), a synthetic 33-amino-acid peptide and a long-acting GLP-2 analogue, enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum.
-
25-Hydroxycholestero...
25-Hydroxycholesterol is a steroid derivative that suppresses the cleavage of sterol regulatory element binding proteins (SREBPs).
